X0508 4 2026-02-04 0001438533 Travere Therapeutics, Inc. TVTX 0001943192 Cline Christopher R. C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, STE 300 SAN DIEGO CA 92130 false true false false CHIEF FINANCIAL OFFICER 1 Common Stock 2026-02-04 4 S 0 1635 32.14 D 111336 D Common Stock 2026-02-04 4 S 0 110 32.90 D 111226 D This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. The weighted average sale price for the transaction reported was $32.14, and the range of prices were between $31.645 and $32.645. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. /s/ Elizabeth E. Reed, Attorney-in-Fact 2026-02-04